CD16/IL-15/CD33 (161533) Tri-Specific Killer Engagers (TriKes) for the Treatment of CD33+ Hematopoietic Malignancies

Trial Profile

CD16/IL-15/CD33 (161533) Tri-Specific Killer Engagers (TriKes) for the Treatment of CD33+ Hematopoietic Malignancies

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 07 Dec 2017

At a glance

  • Drugs OXS-3550 (Primary)
  • Indications Acute myeloid leukaemia; Haematological malignancies; Myelodysplastic syndromes
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Most Recent Events

    • 03 Dec 2017 Planned initiation date changed from 1 Nov 2017 to 1 Nov 2018.
    • 24 Oct 2017 According to a GT Biopharma media release, the US FDA accepted the transfer of IND for OXS-3550 from the University of Minnesota to GT Biopharma.
    • 23 Oct 2017 Planned initiation date changed from 1 Oct 2017 to 1 Nov 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top